José Rodríguez, MD
,
Allergology Department, University Hospital Calixto García, Havana City, Cuba
Raúl Castro, MD
,
Allergens, National Center of Bioproducts, Havana City, Cuba
Alexis Labrada, PhD
,
Allergens, National Center of Bioproducts, Mayabeque, Cuba
Mirta Alvarez, MD
,
Allergology Department, University Hospital Calixto García, Havana City, Cuba
Mercedes Ronquillo, MD
,
Allergology Department, University Hospital Calixto García, Havana City, Cuba
Mayda González, MD
,
Pedro Fonseca Docent Policlinic, Havana City, Cuba
Bárbara Navarro, MD
,
Allergens, National Center of Bioproducts, Mayabeque, Cuba
Maytee Mateo
,
Allergens, National Center of Bioproducts, Mayabeque, Cuba
Yunia Oliva
,
Allergens, National Center of Bioproducts, Mayabeque, Cuba
Iris García, MD
,
Allergology Department, University Hospital Calixto García, Havana City, Cuba
Irene Enriquez, MD
,
Allergology Department, University Hospital Calixto García, Havana City, Cuba
Background: The specific active immunotherapy, employing vaccine of allergen of mite is a treatment considered as effective for the respiratory allergy and asthma. The sublingual route has minor risk of systematises reactions. The objective of this study was to determine the therapeutic effect and security of sublingual immunotherapy (ITSL) employing the standard vaccine VALERGEN-DP (BIOCEN, CUBA) in a population of asthmatic Cuban patients.
Methods: A phase II Clinical Trials double blind, placebo controlled in a total of 40 adult patients with mild or moderate asthma and specific sensibility preponderant to this mite. Half of patients received drops by sublingual route with growing doses up to 2000 UB.
Results: The treatment was effective in the reduction of clinical symptoms and medication intake as compared to conventional treatment in control group. The cutaneous sensibility to this mite was significant reduced, increasing in 1.9 log. the amount of necessary allergen to provoke a positive Prick Test. An improvement of the lung function was observed with a significant reduction (p<0.05) of expiratory pick flow variability The frequency of local reactions were only 0.58% of administration.
Conclusions: The VALERGEN-DP vaccine is an effective treatment and profitable against asthma in our population and guarantee its generalization in the Allergy Services of our health system.
